What is the recommended duration of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor for a patient who has undergone percutaneous coronary intervention (PCI) with a Resolute Frontier (zotarolimus-eluting) stent?

Duration of DAPT After Resolute Frontier (Zotarolimus-Eluting) Stent

For patients receiving a Resolute Frontier zotarolimus-eluting stent, DAPT duration depends on clinical presentation: at least 6 months for stable ischemic heart disease (SIHD) and at least 12 months for acute coronary syndrome (ACS), using aspirin 81 mg daily plus a P2Y12 inhibitor. 1

Standard DAPT Duration by Clinical Indication

For Stable Ischemic Heart Disease (SIHD)

• P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months after drug-eluting stent implantation 1
• Aspirin 81 mg daily (range 75-100 mg) should be continued indefinitely 1
• After completing 6 months of DAPT without bleeding complications and in patients not at high bleeding risk, continuation beyond 6 months may be reasonable 1

For Acute Coronary Syndrome (ACS)

• P2Y12 inhibitor therapy should be given for at least 12 months after stent implantation, regardless of stent type 1, 2
• Ticagrelor is reasonable to use in preference to clopidogrel for maintenance therapy 1, 2
• Prasugrel is reasonable over clopidogrel in patients without high bleeding risk and no history of stroke/TIA 1, 2
• Aspirin 81 mg daily should be continued with the P2Y12 inhibitor 1, 2

Shortened DAPT Duration Considerations

Recent evidence supports shorter DAPT durations (1-3 months) in selected patients with subsequent transition to P2Y12 inhibitor monotherapy to reduce bleeding risk. 3

• In selected patients undergoing PCI, shorter-duration DAPT (1-3 months) followed by P2Y12 inhibitor monotherapy is reasonable to reduce bleeding events 3
• A 3-month DAPT duration followed by high-potency P2Y12 inhibitor monotherapy (not aspirin) demonstrates favorable outcomes 4
• This approach decreases net adverse clinical events without impacting major adverse cardiovascular events at 1 year 4

High Bleeding Risk Scenarios

For SIHD Patients

• Discontinuation of P2Y12 inhibitor after 3 months may be reasonable in patients who develop high bleeding risk (e.g., need for oral anticoagulation, major surgery planned, significant overt bleeding) 1

For ACS Patients

• Discontinuation of P2Y12 inhibitor after 6 months may be reasonable in patients who develop high bleeding risk or significant overt bleeding 1, 2

Extended DAPT Beyond Standard Duration

For SIHD Patients

• Continuation of DAPT beyond 6 months may be reasonable in patients who have tolerated therapy without bleeding complications and are not at high bleeding risk 1

For ACS Patients

• Continuation of DAPT beyond 12 months may be reasonable in patients who have tolerated therapy without bleeding complications and are not at high bleeding risk 1, 2
• For patients with complex multivessel disease or high ischemic risk, extended DAPT should be considered 2
• After completing 12 months, ticagrelor 60 mg twice daily (reduced dose) plus aspirin may be continued in high-risk patients 2, 5

Choice of P2Y12 Inhibitor

The selection of P2Y12 inhibitor impacts both efficacy and bleeding risk:

• Ticagrelor is preferred over clopidogrel for ACS patients treated with stent implantation 1, 2, 6
• Prasugrel is reasonable over clopidogrel in ACS patients without stroke/TIA history and not at high bleeding risk 1, 2
• Prasugrel must not be used in patients with prior stroke or TIA due to increased bleeding risk 1, 2, 6
• Clopidogrel remains appropriate for patients with contraindications to more potent P2Y12 inhibitors 7, 6

Aspirin Dosing

• Daily aspirin dose of 81 mg (range 75-100 mg) is recommended when used as part of DAPT 1, 2, 6
• Higher aspirin doses increase bleeding without improving efficacy 2, 6

Bleeding Risk Mitigation Strategies

• Proton pump inhibitor (PPI) should be prescribed with DAPT to reduce gastrointestinal bleeding risk 6
• Radial artery access for PCI reduces bleeding and vascular complications compared to femoral approach 3, 6
• Annual reassessment of bleeding and ischemic risk is essential for patients on extended DAPT 2

Common Pitfalls to Avoid

• Do not prematurely discontinue DAPT within the first month after stent placement without compelling reasons, as this dramatically increases thrombotic risk 2, 6
• Do not use aspirin doses >100 mg daily when combined with a P2Y12 inhibitor 2, 6
• Do not fail to prescribe a PPI with DAPT, as this simple intervention significantly reduces gastrointestinal bleeding 6
• Do not use prasugrel in patients with history of stroke or TIA 1, 2, 6
• Do not continue ticagrelor 90 mg twice daily for prolonged therapy beyond 12 months—the approved dose for long-term secondary prevention is 60 mg twice daily 2

Algorithmic Approach to DAPT Duration

1. Determine clinical presentation: SIHD vs ACS 1, 2
2. Assess baseline bleeding risk using clinical factors (prior bleeding, anticoagulation need, planned surgery) 1, 2
3. Standard duration: 6 months for SIHD, 12 months for ACS 1, 2
4. Consider shortened duration (1-3 months) in selected patients with acceptable ischemic risk, followed by P2Y12 monotherapy 3, 4
5. Consider early discontinuation (3-6 months) if high bleeding risk develops 1, 2
6. Consider extended duration (>12 months) in ACS patients with high ischemic risk who tolerate DAPT without bleeding 1, 2
7. Reassess annually for changes in bleeding or ischemic risk 2